ASH Research Collaborative News
This report details the initiative’s mission, history, achievements to date, and its promising trajectory toward improving the lives of individuals affected by Sickle Cell Disease.
The ASH Research Collaborative (ASH RC) welcomes new directors to its Board of Directors and announces updates to Board leadership, effective January 1, 2026.
Five early-career investigators are the recipients of the ASH RC SCD Data Hub Award, which is designed to support the next generation of SCD researchers. Under this award, advanced career SCD researchers will partner with and serve as dedicated mentors to early career investigators through every stage of project development, from concept to study completion.
A new study based on multi-site data from the ASH Research Collaborative (ASH RC) Data Hub showcases an automated approach to subclassifying similar genotypes of sickle cell disease using data from electronic health records.
New data finds that the sickle cell drug voxelotor was not associated with any clear indicator of harm to patients, but had limited benefits overall. The findings were based on data pulled from the ASH Research Collaborative (ASH RC) Data Hub.
Research using data from the ASH Research Collaborative (ASH RC) Data Hub aims to define “functional high-risk” multiple myeloma, suggesting that newly diagnosed patients whose disease progresses within 30 months of a triplet or quadruplet drug regimen have poorer outcomes than those who progress after 30 months.
New research showcases a first-of-its-kind artificial intelligence algorithm to examine the dynamics underlying chronic kidney disease in individuals living with sickle cell disease. The algorithm employed data from the ASH Research Collaborative (ASH RC) Data Hub.
The ASH Research Collaborative (ASH RC) conducted research among individuals involved in its national and local sickle cell disease community advisory boards (CABs) to assess clinical trial literacy, and found that even among engaged advocates, there were knowledge gaps about clinical trials.
The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
